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ABSTRACT
This article deals with the question  of the influence  of  preparations that contain pharmacological  
doses of iodine on the functional activity of the thyroid gland. In the practice of a cardiologist amiodarone 
and x-ray contrasting substances are often used that may induce thyroid disorders in many ways, followed 
by hypothyroidism and thyrotoxicosis development.
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INTRODUCTION
The epidemiology of thyroid pathology is charac-
terized by a unique feature which manifests itself, 
firstly, in the fact that it directly depends on the 
level of iodine intake in one population or another. 
Secondly, the thyroid gland is an organ that, due to 
unknown reasons so far, is more likely to develop 
autoimmune processes than others. Thus, iodine 
deficiency and autoimmune thyroidism are among 
the most common non-infectious human patho-
logies.
Due to the prevalence of drugs containing phar-
macological doses of iodine (more than 1 mg per 
day) in clinical practice, it is relevant to study their 
effect on the functional activity of the thyroid gland. 
In the practice of the cardiologist such drugs com-
prise primarily amiodarone and iodine-containing 
X-ray contrast agents that are capable of inducing 
numerous thyroid disorders, with the subsequent 
development of both hypothyroidism and hyperthy-
roidism [2, 5, 7, 11, 13, 18, 22].
For cardiologists, the study of this issue is es-
pecially important, given the direct effect of the 
functional state of the thyroid gland on the cardi-
ovascular system. It is known that one of the im-
portant complications of thyroid dysfunction, even 
at the subclinical stage, is an increase in morbidity 
and mortality of the population due to cardiac 
pathology [12, 25, 26]. According to the Rotter-
dam study, subclinical hypothyroidism is considered 
as independent of cholesterol, body mass index, 
smoking and β-blockers, and is a risk factor for ath-
erosclerosis in the aorta and myocardial infarction 
in elderly women. It has been clearly demonstrated 
that the risk of developing aortic atherosclerosis 
increases by 1.7 times, and myocardial infarction 
by 2.3 times [15].
Some authors report a significantly higher 
risk of coronary heart disease and overall mor-
tality among middle-aged and elderly men with 
latent hypothyroidism. As J.P. Walsh et al. (2005) 
described, ischemic heart disease among patients 
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with hypothyroidism is more likely to be found 
in comparison with euthyroid individuals (odds 
ratio 2.2, p < 0.01), with a significant associa-
tion with coronary artery disease only in patients 
with TSH > 10 mU/l [31]. According to the same 
study, the probability of death and non-lethal co-
ronary events was higher at subclinical (risk of 1.7; 
p < 0.01) and very high levels of manifested hypo-
thyroidism (risk 2.6; p <0.01). In this case, the fre-
quency of myocardial infarction, congestive heart 
failure and the lethal consequences in patients with 
hypothyroidism is twice as high when compared 
with euthyroid individuals [14].
In elderly patients, thyrotoxicosis, which is asso-
ciated with an increased heart rate and increased 
metabolic rate, can become a trigger factor in the 
manifestation of coronary heart disease or signi-
ficantly impair coronary disease and, in some cases, 
may lead to the development of myocardial infarc-
tion [25, 32]. In this context, the increased mortality 
rate of patients with both subclinical and manifest 
thyrotoxicosis from cardiovascular diseases, in par-
ticular coronary heart disease when compared with 
euthyroid patients, has been repeatedly demonstrat-
ed [16, 28, 32]. After an ischemic heart disease, 
hyperthyroidism (including latent) is one of the most 
important causes of the occurrence of absolute car-
diac arrhythmias, in particular, which was proven 
within the framework of the authoritative Fram-
ingham study [10]. This meta-analysis conducted 
showed that the risk of mortality in patients with 
subclinical thyrotoxicosis, including cardiovascular 
disease, was 41% higher than that of subjects with 
euthyroidism [14].
AMIODARONE AND IODINE-CONTAINING 
CONTRASTS
Amiodarone is a lipophilic substance, is a benzofuran 
derivative, characterized by a structural similarity to 
thyroxine and contains a significant proportion of 
iodine — about 75 mg of iodine in one tablet, of 
which about 9 mg enters the thyroid gland directly 
in the form of free particles. Such a large iodine load 
leads to a sharp increase in iodine levels in urine, 
which is sometimes stored up to 6 months after the 
drug is discontinued. The half-life of amiodarone 
lasts from 20 to 100 days [11]. Using iodine-contain-
ing X-ray contrast agents (by computer tomography 
or angiography) leads to the admission of about 
13.5 mg of free iodine to the human body [20].  
The frequency of thyroid dysfunction with pro-
longed use of amiodarone is 30–40%. The follow-
ing have been distinguished as being among the 
mechanisms of the effect of amiodarone on the 
thyroid gland: inhibition of deiodinase types I and II; 
inhibition of the interaction of triiodothyronine with 
α- and β-receptors; the effect on the expression of 
the T3 receptor gene, adrenoreceptors, and myosin 
in the myocardium; and direct cytotoxic action on 
the thyroid gland [2, 6, 8, 17].
IODINE-INDUCED HYPOTHYROIDISM
Iodine-induced hypothyroidism usually develops in 
patients who are susceptible to the effects of inhib-
iting doses of iodine on the thyroid gland. Euthy-
roid individuals with chronic autoimmune thyroid-
itis, asymptomatic carriers of anti-thyroid antibod-
ies, patients with subclinical hypothyroidism, along 
with patients who have had radioiodine therapy or 
subtotal resection of the thyroid gland in the past 
are particularly prone to the development of io-
dine-induced hypothyroidism [6, 11, 21]. One study 
demonstrated that the administration of excess io-
dine in patients with Hashimoto’s thyroiditis caused 
hypothyroidism in 60% of cases [30]. Other studies 
have shown that hypothyroidism develops in almost 
75% of euthyroid patients with anti-thyroid anti-
bodies in long-term treatment with amiodarone [3].
According to the literature, this thyroid dys-
function is observed in 5–32% of patients taking 
amiodarone and is usually transient in patients with-
out prior thyroid disease [6, 11, 30]. Although after 
the drug is discontinued the euthyroid condition 
is usually restored, it may take several months for 
this to happen due to the prolonged half-life peri-
od [21, 30]. According to the results of studies on 
the introduction of iodine-containing X-ray contrast 
agents during coronary angiography, this leads to 
the development of hypothyroidism in 3.5% of cases 
and the deterioration of its course in 12.3% [13].
Clinical manifestations of amiodarone-induced 
hypothyroidism may be transient or permanent, 
subclinical or manifested, their severity depending 
on the background state of the thyroid gland. In 
the presence of chronic autoimmune thyroiditis, 
persistent hypothyroidism usually develops. In this 
case, the development of hypothyroidism on the 
background of treatment with amiodarone is not 
accompanied by a decrease in its therapeutic ef-
fect. The withdrawal of the drug in some patients 
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may restore the euthyroid condition. Verification 
of amiodarone-induced hypothyroidism is not 
a contraindication to continuing treatment with 
amiodarone (Fig. 1). In the case of continued treat-
ment, substitution therapy with L-thyroxine in small 
doses is prescribed until reaching the optimal target 
TSH level at the upper limit of the reference range 
[6, 11, 21, 30].
IODINE-INDUCED THYROTOXICOSIS
The basis of amiodarone-induced thyrotoxicosis is 
the excess synthesis and secretion of thyroid hor-
mones — type 1, or the destruction of thyroid cells 
and the release of excess hormones in the blood 
— type 2 (Tab. 1) due to the effects of amiodarone 
on follicular thyroid cells [4, 27, 32]. Occasionally 
there are mixed forms. According to the results of 
studies, amiodarone-induced thyrotoxicosis deve-
lops in 12–20% of patients receiving this drug. In 
both cases, even after the cancellation of amiodar-
one, due to the long half-life of the drug, thyroto-
xicosis may be sustained for a long time, sometimes 
up to 6 months [24, 32].
One of the earliest manifestations of amiodar-
one-induced thyrotoxicosis is the loss of the antiar-
rhythmic effect of amiodarone. The clinical picture 
is dominated by cardiovascular and mental disor-
ders. There is an exacerbation of arrhythmias, the 
progression symptoms of coronary heart disease 
and heart failure. The risk of developing amioda-
rone-induced thyrotoxicosis does not depend on 
the cumulative dose of the drug, may develop un-
predictably and in a sufficiently short time [1, 4, 11].
Iodine-induced thyrotoxicosis occurs after the 
administration of iodine-containing X-ray contrast 
agents in 0.1–1.2% of patients without concomitant 
thyroid disease. Instead, in patients with thyroid 
diseases, this happens much more often, namely in 
5.2% of cases. As for the treatment of amiodarone 
and with the use of iodine-containing X-ray drugs, 
the risk factors are: advanced age, the presence of 
nodular goitre, lowered TSH and place of living in 
the iodine-deficient region [13].
Unlike amiodarone-induced hypothyroidism, 
treatment of iodine-induced thyrotoxicosis is more 
individual and differentiated. In patients with mild 
thyrotoxicosis, a small goitre and lack of back-
ground thyroid disease, it is sufficient to discontinue 
amiodarone. In patients with thyroid diseases, thy-
rotoxicosis usually does not disappear, even within 
a few months after discontinuation of the drug.
Treatment of amiodarone-induced thyrotoxico-
sis type 1 consists of the administration of high 
doses of thyreostatics (thiamazole 40–60 mg/day, 
carbimazole 60–90 mg/day, propylthiouracil 400– 
–600 mg/day), as well as potassium perchlorate 
(600–1000 mg/day) and lithium (600–900 mg/day). 
In situations of the ineffectiveness of medication 
therapy, a thyroidectomy is conducted in some cases 
[9, 23, 29]. 
Table	1.	Differences	between	amiodarone-induced	thyrotoxicosis	1	and	2	type
Signs AmIT 1 type AmIT 2 type
Pathogenesis Iodine-induced hyperthyroidism Destructive thyroiditis
Background pathology of thyroid gland Often No
Goiter Mostly multimodal goiter Absent or small
Manifestation Early (weeks) Late (months)
Clinical course Difficult Medium-difficult
Dopplerography High blood flow Weakened blood flow
Thyroglobulin Normal High
Response to therapy Unsatisfactory Good
Development of hypothyroidism No Possible
The severity of hypothyroidism
TSH ‹ 10 m U/L
The control of TSH-level 
every 3–6 months
TSH › 10 m U/L
Substitution therapy with 
L-thyroxine
FIGURE 1. Medical tactics by amiodarone-induced hypothyroidism
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In the treatment of amiodarone-induced type 2 thy-
rotoxicosis, the preference is given for glucocorticorti-
coids. The recommended starting dose is 1 mg/kg/day 
followed by a dose reduction every 2 weeks and a total 
duration of 3–5 months. Premature discontinuation of 
prednisolone is accompanied by a recurrence of thyro-
toxicosis and the need for a renewal of treatment.  In 
the case of the development of hypothyroidism, L-thy-
roxine is prescribed additionally [1, 9, 23].
The combination of amiodarone-induced thyro-
toxicosis is based on combined therapy with thiothio-
amides (medium or high doses) and glucocorticoids 
(0.5 mg/kg/day). After normalizing the content of 
thyroid hormones, the dose of both drugs is gra dually 
reduced, prednisolone being discontinued first. The 
duration of combination therapy is 3–5 months.  In 
cases of resistance to medical treatment, or the pres-
ence of a background nodular goitre, surgical inter-
vention on the thyroid gland is performed [2, 9, 23].
PRACTICAL RECOMMENDATIONS
Considering the widespread use of amiodarone and 
iodine-containing X-ray contrast agents in clinical 
practice, it is recommended to take into account 
the function and condition of the thyroid gland 
before their administration, in particular for the 
prevention of iodine-induced disorders. In particu-
lar, prior to the appointment of amiodarone or 
a procedure using iodine-containing X-ray drugs, 
it is recommended that the following examinations 
be performed: determination of TSH levels; thy-
roid peroxidase antibodies; and thyroid gland ultra-
sonography [2, 17]. 
Thus, it is possible to identify patients who are 
at high risk for the development of iodine-induced 
thyroid disease and to conduct their further ob-
servation, in order to correct anomalies in a timely 
manner. In the case of a patient with a node in the 
thyroid gland of a diameter greater than 1 cm found 
by ultrasonography, it is recommended to perform 
scintigraphy. In the treatment of amiodarone in the 
normal ascending functional state of the thyroid 
gland, it is recommended to conduct an examina-
tion 3 months after reaching the cumulative dose of 
the drug and subsequently every 6 months [11, 17].
CONCLUSIONS
 Before prescribing amiodarone and procedures us-
ing iodine-containing X-ray diffraction agents, their 
effects on the thyroid gland should be taken into 
account. In order to identify patients at risk for the 
development of iodine-induced thyropathy,  an ex-
amination of thyroid gland is recommended includ-
ing determination of TSH levels, peroxidase antibod-
ies, and ultrasonography. If these parameters are 
normal, it is recommended that they be monitored 
every 6 months during amiodarone treatment. In the 
case of iodine-induced thyroid disease, treatment is 
prescribed in accordance with the recommendations.
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